NCT00743470 arm group 3e455472f31a889a6b9ab7084cbd1798 [clinicaltrials_resource:NCT00743470/arm-group/3e455472f31a889a6b9ab7084cbd1798]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00743470 arm group 3e455472f31a889a6b9ab7084cbd1798 [clinicaltrials_resource:NCT00743470/arm-group/3e455472f31a889a6b9ab7084cbd1798]
Bio2RDF identifier
NCT00743470/arm-group/3e455472f31a889a6b9ab7084cbd1798
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 455472f31a889a6b9ab7084cbd1798
description [clinicaltrials_vocabulary:description]
Group 1 receives regimen A and ...... tonavir 200/50 mg tablets BID.
identifier
clinicaltrials_resource:NCT00743470/arm-group/3e455472f31a889a6b9ab7084cbd1798
title
NCT00743470 arm group 3e455472f31a889a6b9ab7084cbd1798
@en
type
label
NCT00743470 arm group 3e455472 ...... 55472f31a889a6b9ab7084cbd1798]
@en